Suhagra is one of the better documented India-market sildenafil brands because Cipla publishes individual product records for Suhagra 25 mg, 50 mg and 100 mg tablets. The same official list also identifies Suhagra Force 50 as a combination of sildenafil and dapoxetine. This provides a concrete distinction between sildenafil-only Suhagra products and a separately named combination, rather than relying on anonymous online catalogs.
In Cipla’s product listing, the ordinary Suhagra tablets contain sildenafil citrate in strengths corresponding to 25, 50 and 100 mg sildenafil. Suhagra Force 50, however, lists sildenafil 50 mg together with dapoxetine hydrochloride 30 mg. The presence of two drugs is a medically important difference. The combination should not be described as a stronger or interchangeable version of a simple sildenafil tablet.
This page explains the precise Cipla records, company attribution and how product identity relates to U.S. regulatory status. It does not provide combination prescribing or import instructions. See the Indian-brand directory for other named products, or the U.S. generic sildenafil guide for approved domestic medicines.
Unlike brands known mainly through independent export shops, Suhagra can be researched from a named pharmaceutical company’s own structured generic-product list. The record associates the Suhagra brand with sildenafil citrate tablets and explicitly separates Suhagra Force. This supports identifiable formulation statements, although it does not independently establish current retail stock or a specific pack’s authenticity.
The table below preserves the distinction between the single-ingredient tablets and the combination product. These are product catalog entries, not instructions on whether or how an individual should take them.
| Cipla listing | Named active ingredients | Product distinction |
|---|---|---|
| SUHAGRA 25MG | Sildenafil citrate, labeled as 25 mg | Single-ingredient sildenafil tablet |
| SUHAGRA 50 | Sildenafil citrate, labeled as 50 mg | Single-ingredient sildenafil tablet |
| SUHAGRA 100 4’S | Sildenafil citrate, labeled as 100 mg | Single-ingredient tablet; company catalog gives a pack designation |
| SUHAGRA FORCE 50 | Sildenafil citrate 50 mg + dapoxetine HCl 30 mg | Two active ingredients; not interchangeable with ordinary Suhagra |
Cipla’s own generic-product listing is a direct company-level connection to Suhagra, more reliable for product naming than descriptions lifted from unrelated sellers. That listing still must not be overread as a batch-level manufacturing certificate or an assurance that every Suhagra-looking package sold online comes from Cipla.
On a finished medicine pack, manufacturing and marketing details may identify different legal entities or sites. The published Cipla connection is strong evidence for the product family; exact factory, lot and regulatory license statements need the original presentation’s documentation.
The three ordinary Suhagra entries are all described as sildenafil-citrate tablets, with strengths expressed in milligrams. This gives the reader actual product-specific information rather than just a statement that the brand has “various doses.” It also helps prevent confusion with unrelated Cipla sildenafil names such as Silagra.
These Indian product listings should not be turned into personal dose recommendations. U.S. Viagra ED tablets also have 25, 50 and 100 mg strengths, but matching numbers alone does not mean FDA has approved Suhagra or found it therapeutically equivalent to a U.S. generic. See approved U.S. strengths for the separate domestic catalog.
Suhagra Force 50 is distinctly identified in Cipla’s catalog as sildenafil together with dapoxetine. This matters because dapoxetine is another active ingredient with its own risks, interactions and regulatory considerations. A comparison that reduces Force to “Suhagra 50 with extra strength” would be materially wrong.
No dosing or substitution conclusion follows from the compound name. A reader interested in sildenafil-only ED tablets should compare only the plain Suhagra entries; the Force product requires separate assessment. Do not mix it into a one-active-ingredient sildenafil formulation table.
Cipla’s product list also names Silagra 100, described as sildenafil film-coated tablets. That is a different brand string from Suhagra, even though both names appear under the same broad PDE-inhibitor product group. In search results these words can look nearly interchangeable and are easy to confuse.
For accurate product identity, record the exact printed brand and presentation, not just the company name or ingredient. Suhagra 100 and Silagra 100 should not be treated as the same trade-name product without checking the designated listing.
The existence of a Cipla corporate product entry is meaningful support for Suhagra’s Indian product identity. It does not automatically grant an FDA-approved U.S. application to that trade name. Approval, labeling and therapeutic-equivalence status must be determined for a specific U.S. drug application rather than for a company or ingredient in general.
The distinction is explained in brand versus generic ED products and U.S. generic sildenafil. Any comparison to Viagra must be framed around declared ingredients and separate marketing authorizations.
Plain Suhagra tablet entries contain sildenafil, a PDE5 inhibitor with important contraindications involving nitrates and riociguat. Cardiovascular conditions and interacting drugs also require clinical screening. Suhagra Force adds another declared ingredient, so its medical profile cannot be inferred from sildenafil alone.
Seek emergency help for an erection lasting longer than four hours or other serious symptoms. The ingredient-level interaction guide and side-effects guide cover the standard sildenafil safety context without claiming to approve India-market combination use.
A pharmacy listing may show a pack count, a local product status or a company attribution. Those facts should not be confused with the stronger claim that one particular pack is a verified authorized U.S. medicine. Even when a product name matches Cipla’s list, the particular batch, location and selling pharmacy remain separate issues.
A useful comparison records active ingredients, strength, exact suffix and company role. Prices and retailer promotions change, so this page intentionally does not quote them or publish vendor rankings.
U.S. approval and lawful dispensing are different questions from whether an Indian manufacturer lists Suhagra. Overseas offerings do not create a routine exemption from U.S. import rules for unapproved prescription drugs. A seller promising no prescription or automatic overseas delivery should not be described as a standard pharmacy route.
For evaluation and dispensing of U.S.-approved ED medicines, use the prescription guide and the lawful pharmacy access guide.
Suhagra’s distinctive feature is the exact Cipla listing, including its three plain sildenafil strengths and a separately identified sildenafil–dapoxetine product. Caverta is connected to a different Indian manufacturer’s published 25/50/100 portfolio, while Kamagra has a specific Ajanta-marketed tablet record plus less certain oral-jelly claims.
These differences in documentary evidence are more useful than generic comparisons about one Indian brand being “more powerful.” The larger context is indexed at Indian sildenafil brands.
Cipla includes Suhagra in its corporate generic-product list with specific sildenafil tablet entries.
The company list names Suhagra 25 mg, 50 mg and 100 mg sildenafil tablets.
Cipla lists sildenafil citrate 50 mg together with dapoxetine hydrochloride 30 mg, making it a two-ingredient product.
No automatic substitution follows. Force contains an additional medicine and requires its own clinical and regulatory assessment.
No. Cipla lists both under its product portfolio; the names describe separately designated products.
No. Corporate Indian product listings do not establish FDA approval of that branded product in the United States.
No. Similar active ingredients and numbers do not replace the U.S. product-specific approval and therapeutic-equivalence framework.
A licensed clinician may prescribe an appropriate FDA-approved sildenafil ED medicine dispensed by a licensed U.S. pharmacy.